

Docket No.: I0248.70024US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Adams et al.

Serial No.:

10/616409

Confirmation No.:

9289

Filed:

July 9, 2003

For:

BOROPROLINE COMPOUND COMBINATION THERAPY

Examiner:

B. J. Fetterolf

Art Unit:

1642

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown

Dated: July 26, 2005

TRANSMITTAL

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is/are the following document(s):

[X]Response to Restriction Requirement

[X]Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

No fee is due. If a fee is due, it may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Dated: July 28, 2005

x07/28/05x

Respectfully submitted.

Maria A. Trevisan, Reg. No. 48,207 WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza 600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000



Docket No.: I0248.70024US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Adams et al.

Serial No.:

10/616409

Confirmation No.:

9289

Filed:

July 9, 2003

For:

BOROPROLINE COMPOUND COMBINATION THERAPY

Examiner:

B. J. Fetterolf

Art Unit:

1642

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown

below.

Dated: July 25, 2005

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed from the United States Patent and Trademark Office on June 28, 2005 (Paper No. 1), Applicant hereby requests entry of the following election.

Election

Applicant hereby elects Group I (claims 1-17, 25, 139, 142, 144, 166, 210, 251-259 and 338), drawn to a method for stimulating an immune response in a subject comprising administering to a subject in need of immune stimulation an agent of Formula I, and an antibody or antibody fragment, in an amount effective to stimulate an immune response, wherein the subject is suffering from cancer, classified in class 424, subclass 155.1.

Applicant further elects

- i) a species of antibody that is rituximab (Rituxan), and
- ii) a species of cytokine that is IL-1.